Shire (SHPG) Q2 2012 Earnings Call August 01, 2012 9:00 am ET Executives Eric Rojas - Director of Investor Relations - North America Angus C. Russell - Chief Executive Officer, Interim President of Specialty Pharma and Executive Director Graham Hetherington - Chief Financial Officer, Principal Accounting Officer and Director Sylvie L. Gregoire - President of Human Genetic Therapies Business and Member of Management Committee Kevin L. Rakin - Chief Executive Officer of Advanced Biohealing and President of Regenerative Medicine Analysts Ken Cacciatore - Cowen and Company, LLC, Research Division Peter Verdult - Morgan Stanley, Research Division William Tanner - Lazard Capital Markets LLC, Research Division Brian Bourdot - Barclays Capital, Research Division Jo Walton - Crédit Suisse AG, Research Division Frank H. Pinkerton - SunTrust Robinson Humphrey, Inc., Research Division David G. Buck - The Buckingham Research Group Incorporated David Amsellem - Piper Jaffray Companies, Research Division PresentationOperator
Hello, and welcome to Shire's 2012 Second Quarter Results Call. [Operator Instructions] Just to remind you, this conference call is being recorded. Today, I'm pleased to present Eric Rojas. Please begin your call. Eric Rojas Good morning and good afternoon, everyone. Thank you for joining us today for Shire's Second Quarter 2012 Financial Results. By now, you should have all received our press release and should be viewing our presentation via our website on shire.com. If for some reason you have not received the press release or are unable to access our website, please contact Souheil Salah in our U.K. Investor Relations department on +44-1256-894-160, as he will be happy to assist you.